Clinical Trial

Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors

Name: Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors — clinical trial record (NCT07671534)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: GEMINI

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is an open label phase II study using metronomic low-dose gemcitabine and mitomycin c given intravenously, and thalidomide administered orally, for patients with advanced solid tumors.

Trial Details

NCT Number	NCT07671534
Lead Sponsor	Sarcoma Oncology Research Center, LLC
Conditions	Solid Tumor Cancer
Enrollment	60 participants
Start Date	2026-06
Primary Completion	2029-06 (estimated)
Study Completion	2029-06 (estimated)
Updated on ClinicalTrials.gov	2026-06-26